Paper · 36545708
References75
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 75
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12673442 | Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). | J Gastroenterol | 2003 | https://conductscience.org/library/papers/12673442 | PubMed |
| 2 | 35464283 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). | Hepatobiliary Surg Nutr | 2022 | https://conductscience.org/library/papers/35464283 | PubMed |
| 3 | 35978604 | Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. | Liver Cancer | 2022 | https://conductscience.org/library/papers/35978604 | PubMed |
| 4 | 29628281 | EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. | J Hepatol | 2018 | https://conductscience.org/library/papers/29628281 | PubMed |
| 5 | 33877527 | Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. | Hepatol Int | 2021 | https://conductscience.org/library/papers/33877527 | PubMed |
| 6 | 34143971 | Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34143971 | PubMed |
| 7 | 26146815 | World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. | Hepatology | 2015 | https://conductscience.org/library/papers/26146815 | PubMed |
| 8 | 30665869 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30665869 | PubMed |
| 9 | 22105822 | Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/22105822 | PubMed |
| 10 | 33317248 | Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. | Clin Mol Hepatol | 2021 | https://conductscience.org/library/papers/33317248 | PubMed |
| 11 | 33653656 | Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. | Acad Radiol | 2021 | https://conductscience.org/library/papers/33653656 | PubMed |
| 12 | 19725152 | Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. | World J Gastroenterol | 2009 | https://conductscience.org/library/papers/19725152 | PubMed |
| 13 | 29420221 | Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29420221 | PubMed |
| 14 | 12479938 | Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. | Hepatol Res | 2002 | https://conductscience.org/library/papers/12479938 | PubMed |
| 15 | 34754838 | Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study. | J Hepatocell Carcinoma | 2021 | https://conductscience.org/library/papers/34754838 | PubMed |
| 16 | 34185551 | Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34185551 | PubMed |
| 17 | 35284529 | Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative study. | Hepatobiliary Surg Nutr | 2022 | https://conductscience.org/library/papers/35284529 | PubMed |
| 18 | 32897657 | Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. | Liver Transpl | 2021 | https://conductscience.org/library/papers/32897657 | PubMed |
| 19 | 29624699 | Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. | Hepatology | 2018 | https://conductscience.org/library/papers/29624699 | PubMed |
| 20 | 29995681 | Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients. | Ann Surg | 2020 | https://conductscience.org/library/papers/29995681 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/36545708/references